Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

By P. Ridker, Samuel Z. Goldhaber, E. Danielson, Y. Rosenberg, C. Eby, S. Deitcher, M. Cushman, S. Moll, C. Kessler, C. Elliott and 7 more. New England Journal of Medicine, 2003

777 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Guidelines on oral anticoagulation with warfarin – fourth edition (2011, background): “Specifying tighter target ranges for fully anticoagulated patients e.g. 2Æ0–2Æ5 or 3Æ5–4Æ0 does not achieve tighter anticoagulation control but results in more blood tests and more INR results in ranges associated with increased risk of thrombosis and bleeding (Meier et al, 2007).”
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008, background): “…approaches to establish the most appropriate range for different indications, as follows: (1) randomized trials in which patients are assigned to two different target ranges 142–145, 152, 153 ; (2 ) indirect Fixed minidose warfarin (1 mg daily) has been evaluated in a number of clinical settings.”
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. (2003, background): “Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventio”